{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:45Z","timestamp":1791397305008,"version":"4.3.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ymgme.2013.07.005","type":"journal-article","created":{"date-parts":[[2013,7,14]],"date-time":"2013-07-14T04:47:43Z","timestamp":1373777263000},"page":"405-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain"],"prefix":"10.1016","volume":"110","author":[{"given":"Mahoko","family":"Furujo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2013.07.005_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0205","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.07.005_bb0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"FOS European Investigators, Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermott","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of a-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease: absence of editing of human a-galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International Collaborative Fabry Disease Study Group, Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0050","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2013.07.005_bb0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0060","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long term renal stabilization after 54months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0070","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.clinthera.2009.09.008","article-title":"Effect of agalsidase alfa replacement therapy on Fabry disease related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis","volume":"31","author":"Kampmann","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0075","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2013.07.005_bb0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0085","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jpeds.2009.11.007","article-title":"Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease","volume":"156","author":"Schiffmann","year":"2010","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0090","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.07.005_bb0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/hmg\/3.4.667","volume":"3","author":"Davies","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0100","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"Tondel","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"FOS Investigators. Fabry disease and the skin: data from FOS, the Fabry Outcome Survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0225","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2133.2012.10742.x","article-title":"Angiokeratoma: decision-making aid for the diagnosis of Fabry disease","volume":"166","author":"Zampetti","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a consensus in the laboratory diagnostics of Fabry disease \u2014 recommendations of a European expert group","volume":"34","author":"Gal","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"International Fabry Disease Study Group, Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1468-3083.2009.03455.x","volume":"24","author":"Fauchais","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0135","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0145","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","article-title":"Small fiber dysfunction predominates in Fabry neuropathy","volume":"19","author":"D\u00fctsch","year":"2002","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0150","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mus.20174","article-title":"Functional assessment of A delta and C fibers in patients with Fabry's disease","volume":"30","author":"Valeriani","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2013.07.005_bb0155","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0160","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","article-title":"Fabry disease in childhood","volume":"144","author":"Desnick","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-11-61","article-title":"Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel","volume":"11","author":"Burlina","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0170","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1651-2227.2002.tb03110.x","article-title":"Pathophysiology and assessment of neuropathic pain in Fabry disease","volume":"91","author":"Schiffmann","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0180","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10.1016\/j.ymgme.2013.07.005_bb0185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study","volume":"28","author":"Eto","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0190","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2013.07.005_bb0195","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2013.07.005_bb0220","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213002308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213002308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:39:40Z","timestamp":1563410380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719213002308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1096719213002308"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.07.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}